Juvenile myelomonocytic leukemia (JMML) is a rare leukemia of infancy and early childhood. A hallmark of JMML is that JMML cells are selectively hypersensitive to GM-CSF in vitro, but have normal sensitivity to IL-3, which shares the β-subunit receptor with GM-CSF. The pathogenesis of JMML is linked to dysregulated signal transduction through the Ras signaling pathway caused by mutations of RAS, PTPN11 and c-CBL, or loss-of-heterozygosity of NF1. Although most patients with JMML experience an aggressive disease course, some others spontaneously resolve. No specific mutation has been definitively demonstrated to confer a poorer prognosis, with the exception of perhaps PTPN11, which has been shown to be associated with a higher risk of relapse in some series. In addition, gene expression and methylation analyses have identified signatures associated with outcome that are unexpectedly independent of genotype, leading us to believe that additional mutations or events mitigate the course of JMML. Finally, the mechanisms that underlie selective GM-CSF hypersensitivity are not well established in JMML.

We previously reported that constitutively-hyperactive MAPK and Akt were found in 73% and 55% of JMML patients, respectively, and that a tumor suppressor, PTEN, is deficient in 67% of JMML patients. As PTEN functions as an antagonist to the Ras signaling pathway caused by mutations of RAS, PTPN11 and c-CBL, or loss-of-heterozygosity of NF1, it is unlikely that most patients with JMML experience an aggressive disease course, some others spontaneously resolve. In contrast to the data reported in AML, we found that 22/26 (85%) of subjects had substantially lower CREB protein levels than normal controls (Figure 1a). In further quantifying the total CREB protein using ELISA, we found that the median level of CREB protein was significantly lower in JMML subjects (0.62 ng/mg BSA, n = 26) as compared with 7 normal controls (8.8 ng/mg BSA, P = 0.006; Figure 1b). To understand the mechanism underlying CREB deficiency in JMML, we evaluated the mRNA expression of CREB in MNCs from 31 JMML patients using relative quantitative real-time RT-PCR (qRT-PCR). The median of the relative quantity (RQ) of CREB mRNA from patients was significantly lower than that from 17 normal adults (0.42 vs 1.0, P < 0.001, Figure 1c). This indicates that the regulation of CREB transcription is disrupted in JMML. However, there was no linear correlation between CREB mRNA and CREB protein levels in JMML, suggesting that additional mechanism(s) affecting protein levels may be involved. These results, together with the AML data, suggest that a balanced amount of CREB is critical for maintaining cells with proper responsiveness to GM-CSF in hematopoiesis.

Phosphorylation at Ser-133 of CREB is required for the transcriptional activation of early growth response gene-1 (Egr-1) in response to GM-CSF stimulation in hematopoietic cell lines, but not to IL-3 stimulation. Egr-1 upregulates the PTK7 gene. mice lacking Egr-1 exhibit a significant increase in steady-state levels of dividing hematopoietic stem cells (HSCs) in the BM, and a striking spontaneous mobilization of HSCs into blood. Egr-1 has a deterministic role in governing the development of hematopoietic cells along the macrophage lineage. Therefore, we hypothesized that Egr-1 expression may be deficient in JMML because of the deficient transcriptional activation of CREB. We first evaluated Egr-1 protein levels by western blot in MNCs of 24 patients. We found that 21/24 (87%) of subjects were substantially Egr-1 protein deficient (Figure 1a). If additional studies confirm our data, Egr-1 would be the most frequent protein deficiency in JMML. Owing to no commercial ELISA assay being available for Egr-1 protein quantification, we were unable to quantitatively evaluate the levels of Egr-1 protein in JMML. Instead, we quantified Egr-1 expression by real-time RT-PCR in MNCs from patients using relative quantitative real-time RT-PCR (qRT-PCR). The median of the relative quantity (RQ) of Egr1 mRNA from patients was significantly lower than that from 17 normal adults (0.002 vs 1.0, P < 0.001, Figure 1c).
mRNA expression in MNCs from 47 JMML patients using qRT-PCR. We found that Egr-1 expression was only slightly lower in JMML (median 4.30, n = 47) than in normal controls (median 4.66, n = 17, P = 0.05). This indicated that the Egr-1 transcriptional activity was not significantly disrupted in JMML, suggesting a post-transcriptional mechanism is responsible for the decreased Egr-1 protein levels in JMML.

In order to exclude that the decreased expressions of CREB and Egr-1 were caused by sample degradation, we collected cells from expanded CFU-GM derived from MNCs of a normal control BM and three JMML patients. We found that in the presence of 10% fetal bovine serum and rhGM-CSF, both CREB and Egr-1 were deficient in fresh JMML CFU-GM in comparison with the normal control (Figure 1d). This confirms that JMML cells are truly deficient with both CREB and Egr-1.

Mutations are rarely reported in either CREB or Egr-1 genes in patients with leukemia or other forms of cancer. Pigazzi et al. reported that CREB was overexpressed in AML owing to the hypermethylated promoter of mir-34b. Further, knockdown of mir-183 increased Egr-1 and PTEN expression in cancer cells. Interestingly, miR-34b is located on chromosome 11q23, and miR-183 on 7q32. Both of these chromosomal segments are frequently disrupted in JMML. Therefore, we evaluated the expression levels of miR-34b and miR-183 in MNCs from PB or BM of 47 JMML patients. We found a slightly higher median level of miR-34b in JMML subjects (median = 1.4 vs 1.0, P = 0.05, Figure 2a). Strikingly, the median level of miR-183 was significantly higher in JMML compared with normal controls (median = 13.8 vs 4.2, P < 0.001, Figure 2b). Our data suggest that miR-183 may contribute to Egr-1 protein deficiency in JMML, but miR-34b does not have a significant role in CREB deficiency. Interestingly, we also found a significant linear correlation between the expression level of miR-183 and the monocyte percentage in 34 patients who had available clinical data (P = 0.026, Figure 2c). On the basis of a robust regression analysis, for every unit increased in the square root of RQ miR-183, the monocyte percentage significantly increased by 0.73% (i.e., 0.32%, P = 0.05). Unfortunately at present, we do not have access to clinical data to analyze the correlation of miR-183 expression levels with patients' clinical course. However, in further investigating miR-183, attempting a correlation with the known mutational status of PTEN11, NRAS, KRAS and CBL genes in 28 patients with available data (Supplementary Table-S1), we found that miR-183 expression was significantly higher in patients with PTEN11 mutations (median 34.8) than those without (median 6.9, P = 0.002, Figure 2d). We could not make conclusive correlations between miR-183 expression and NRAS, KRAS and CBL mutational status because of limited numbers of patients with these mutations.

In this study, we found that CREB was significantly decreased in JMML, and this decrease may contribute to overexpression of c-Jun in JMML, because of insufficient CREB repression of transcriptional activation on c-Jun. We also found a significant overexpression of miR-183 in JMML, which may contribute to Egr-1 protein deficiency, and further worsen the monocyte accumulation in JMML. This is supported by our finding that the expression levels of miR-183 were significantly linearly correlated with the monocyte percentage in JMML patients. Furthermore, it has been reported that anti-miR-183 treatment leads to increased protein levels of Egr-1 and PTEN in tumor cell lines. Therefore, miR-183 may be a potential biomarker and therapeutic target for JMML. The mechanism of overexpression of miR-183 is unknown in JMML. We found that overexpression of miR-183 was related to PTEN11 mutation. Yang et al. reported that activating PTEN11 mutants increased c-Jun-PU.1 complexes and promoted
monocytic differentiation. It will be interesting to investigate whether increased c-Jun-PU.1 complexes have any role in upregulating miR-183 expression, or overexpression of miR-183 is correlated with any status of chromosome 7q in JMML.

In summary, we identified CREB and Egr-1 as being significantly deficient in JMML, both of which are molecules specifically affecting GM-CSF signaling. We also demonstrated that miR-183 was overexpressed in JMML, which may contribute to the Egr-1 deficiency and possibly the monocyte predominance in JMML. This is the first evidence demonstrating that a microRNA is involved in JMML pathogenesis. Further investigations may reveal how miR-183 is regulated and contributes to dysregulated GM-CSF signaling, and provide more insights to microRNA involvement in the pathogenesis of other forms of leukemia.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This research was supported by the United States of America National Institutes of Health grants UL1 TR000039, R01 CA095621 and R01 HL082959 (PDE and YLL). We thank Priyangi A. Malaviarachchi for expert technical assistance.

NOTE ADDED IN PROOF
While this manuscript was undergoing revision, a manuscript was published by Pigazzi et al., Haematologica, 2012 Oct 25 (published online ahead of print) ‘miR-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation.’ In this manuscript, the authors present some data from JMML patient samples to suggest CREB protein deficiency.

YL Liu1, SY Lensing1, Y Yan1, TM Cooper2, ML Loh3 and PD Emanuel1

1Department of Medicine, Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA;
2Department of Pediatrics, Division of Hematology/Oncology, Emory University, Atlanta, GA, USA and
3Division of Hematology Oncology, University of California Benioff Children’s Hospital, San Francisco, CA, USA
E-mail: ylucyliu@uams.edu or pdemanuel@uams.edu

REFERENCES
1 Kitamura T, Sato N, Arii K, Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 1991; 66: 1165–1174.
2 Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77: 925–929.
3 Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res 2009; 33: 355–362.
4 Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114: 1859–1863.
5 Okl-Byts C, Poetsch AR, Nolle P, Claus R, Zucknick M, Sandrock I et al. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 2011; 117: 4871–4880.
6 Bresolin S, Zecca M, Flotho C, Trentin L, Zangrand A, Sainati L et al. Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia. J Clin Oncol 2010; 28: 1919–1927.
7 Liu YL, Castleberry RP, Emanuel PD. PTPN11 deficiency is a common defect in juvenile myelomonocytic leukemia. Leuk Res 2009; 33: 671–677.
8 Lamph WW, Dwarki VJ, Ofir R, Montminy M, Verma IM. Negative and positive regulation by transcription factor CAMP response element-binding protein is modulated by phosphorylation. Proc Natl Acad Sci USA 1990; 87: 4320–4324.
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

**GADD45A** methylation predicts poor overall survival in acute myeloid leukemia and is associated with **IDH1/2** and **DNMT3A** mutations

**Leukemia (2013) 27** 1588–1592; doi:10.1038/leu.2012.346

Acute myeloid leukemia (AML) is a heterogeneous disease with variable treatment outcome. Despite recent advances in understanding the key molecular mechanisms of myeloid leukemogenesis, risk stratification remains imperfect, particularly in the intermediate risk group in which a large proportion of patients have a normal karyotype. For this group of patients, genetic alterations in genes such as **FLT3**, **NPM1** and **CEPBA**, provide useful prognostic information, but alone are not sufficient to accurately predict prognosis for all patients. Recently, recurrent mutations in epigenetic modifiers such as **IDH1/2**, **DNMT3A**, and **TET2** have been described, but their prognostic significance remains somewhat controversial, and it is unclear if targeted therapies will evolve from identification of these mutations. Identification of target genes that undergo epigenetic modification in the landscape of somatic mutations in epigenetic modifiers is likely to yield important prognostic information, and potentially identify novel biomarkers of response to demethylating agents, which are currently showing promise in the treatment of AML.

Growth arrest and DNA-damage inducible alpha (**GADD45A**) is a tumour suppressor gene that has cell-type specific roles in cellular stress, coordinating DNA repair and de-methylation, cell cycle arrest and pro-apoptotic or pro-survival responses. Although downregulation of **GADD45A** has been linked to the presence of **FLT3-ITD** and **FLT3-TKD** mutants, and recently with RUNX1 c-terminal mutations, there is a broad downregulation of **GADD45A** in AML and other mechanisms associated with this remain to be determined. Previous studies in solid tumours have identified atypical methylation of **GADD45A** at four discrete CpG residues (CpG1–4) ~700 bp upstream of the transcriptional start site, which correlates with gene expression and has been linked to tumour response in vitro and in xenograft models. Here, we assessed DNA methylation of these same key CpG residues in **GADD45A** in AML and determined co-occurrence with other recurrent mutations and impact on patient outcome.

To determine the frequency of **GADD45A** CpG1–4 methylation in AML, we screened a retrospective cohort of 222 newly diagnosed AML cases for methylation of **GADD45A** CpG1–4 using Sequenom MassARRAY on bisulphite converted genomic DNA (amplicon given in Figure 1a). All patients were collected with informed consent with approval from the relevant ethics committees, in accordance with the Declaration of Helsinki. The levels of **GADD45A** CpG1–4 methylation in the patient samples ranged from 0–90% (Figure 1b). As CpG1 methylation was always higher than CpG2–4 methylation it was considered representative of methylation at this discrete region, and **GADD45A** CpG1 hyper-methylation (G45Ahigh) was defined as methylation exceeding 2 s.d. from the mean of the eight normal bone marrow and three normal CD34+ pooled controls (≥12%; Figure 1b). Using this cut-off, 93 of 222 AML patients (42%) were defined as **G45A**high (Figure 1b; Table 1). **G45A**high patients were significantly older than **G45A**low patients with a mean age of 60 vs 55 years (P = 0.02; Table 1). There was also a sex bias with significantly more females than males in the **G45A**high group. Additionally, we found a negative association of **G45A**high with **Inv16** (P = 0.006; Table 1).

To assess co-occurrence with other common mutations in AML we used a PCR-based fragment analysis for **FLT3-ITD** screening and a multiplexed matrix-assisted laser desorption/ionization time-of-flight genotyping approach (Sequenom MassARRAY Compact System, Sequenom, Inc., San Diego, CA, USA) for detection of the following mutations: **KIT** (D816V), **DNMT3A** (R882C/H), **FLT3** (TKD: D835H/Y/V/E, I836DEL, I836NS), **IDH1** (R132C/H), **IDH2** (R140W/L/G, R172W/G/K/M), **JAK1** (T478S, V623A), **JAK2** (V617F), **KRAS** (G12D/V/A, G13D/A) and **WT1** (rs16754). Mutation frequencies are given in Table 1. We subsequently assessed co-association of recurrent mutations with **GADD45A** methylation status. Interestingly, there was a significant association of **G45A**high with **IDH1/2** (P < 0.0001) and **DNMT3A** (P = 0.02) mutations (Table 1, Figure 1c). **IDH1** and **IDH2** mutations were mutually exclusive as reported previously, and 36 of 41 patients (88%, P = 0.0001) with either **IDH1** or **IDH2** mutations were in the **G45A**high patient group (Figure 1c). For **DNMT3A**, 19 of 30 patients were associated with the **G45A**high patient group (63%, P = 0.02). We found no statistical association of **G45A**high with **FLT3-ITD** or other recurrent mutations, and 13 of 93 (14%) **G45A**high patients were negative for all mutations tested.